Shared mechanisms in affective illness, epilepsy, and migraine

Neurology

Volumn 44, Issue 10, 1994, Pages 37-47

  Post, Robert M ^a   Silberstein, Stephen D ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; EPILEPSY; GENE EXPRESSION; HUMAN; KINDLING; MIGRAINE; MOOD DISORDER; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; STRESS;

ANIMAL; EPILEPSY; GENE EXPRESSION; HUMAN; KINDLING (NEUROLOGY); MIGRAINE; MOOD DISORDERS; PAIN; STRESS;

EID: 2542497995     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Merikangas KR, Merikangas JR, Angst J. Headache syndromes and psychiatric disorders: association and familial transmission. J Psychiatr Res 1993;27:197-210.
2. Marks DA, Ehrenberg BL. Migraine-related seizures in adults with epilepsy, with EEG correlation. Neurology 1993;43:2476-2483.
3. Post RM. Alternatives to lithium for bipolar affective illness. In: Tasman A, Goldfinger SM, Kaufmann CA, eds. Review of psychiatry, vol 9. Washington, DC: American Psychiatric Press, 1990:170-202.
4. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura. Neurology 1994; 44:647.
5. Silberstein SD, Saper J. Migraine: diagnosis and treatment. In: Dalessio D, Silberstein SD, eds. Wolffs headache and other head pain. 6th ed. New York: Oxford University Press, 1993:96-170.
6. Feinmann C. Pain relief by antidepressants: possible modes of action. Pain 1985:23:1-8.
7. DeMontigny C, Blier P. Effects of antidepressant treatments on 5-HT neurotransmission. In: Marsden CA, Heal DJ, eds. Central serotonin receptors and psychotropic drugs. Oxford: Blackwell Scientific Publications, 1992:223-238.
8. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990:47:411-418.
9. Silberstein SD. Review: serotonin (5-HT) and migraine. Headache 1994;34:408-417.
10. Humphrey PPA, Hartig P, Hoyer D. A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 1993; 14:233-238.
11. Gilman AG. G proteins and regulation of adenyl cyclase. JAMA 1989;262:1819-1825.
12. Krebs EG. Role of the cyclic AMP-dependent protein kinase in signal transduction. JAMA 1989;262:1815-1818.
13. Berridge MJ. Inositol triphosphate, calcium, lithium, and cell signaling. JAMA 1989;262:1834-1841.
14. Simon MI, Strathmann MP, Gautam N. Diversity of G proteins in signal transduction. Science 1991;252:802-809.
15. Nishizuka Y. The family of protein kinase C for signal transduction. JAMA 1989;262:1826-1833.
16. Pani L, Kuzmin A, Diana M, et al. Calcium receptor antagonists modify cocaine effects in the central nervous system differently. Eur J Pharmacol 1990;190:217-221.
17. Pazzaglia PJ, Post RM, Ketter TA, et al. Preliminary controlled trial of nimodipine in ultra-rapid cycling dysregulation. Psychiatry Res 1993;49:257-272.
18. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999-1010.
19. Weiss SRB, Post RM. Caveats in the use of the kindling model of affective disorders. Toxicol Ind Health (in press).
20. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969;25:295-330.
21. Racine R. Kindling: the first decade. Neurosurgery 1978;3: 234-252.
22. Weiss SRB, Post RM. Development and reversal of conditioned inefficacy and tolerance to the anticonvulsant effects of carbamazepine. Epilepsia 1991;32:140-145.
23. Mathew NT. Chronic refractory headache. Neurology 1993; 43(suppl 3):S26-S33.
24. Post RM, Weiss SRB, Clark M, et al. Amygdala vs local anesthetic kindling: differential anatomy, pharmacology, and clinical implications. In: Wada J, ed. Kindling IV. New York: Plenum Press, 1990:357-369.
25. Post RM, Altshuler LL, Ketter TA, et al. Antiepileptic drugs in affective illness: clinical and theoretical implications. In: Smith DB, Treiman DM, Trimble MR, eds. Advances in neurology, vol 55: neurobehavioral problems in epilepsy. New York: Raven Press, 1991:239-277.
26. Goddard GV, Douglas RM. Does the engram of kindling model the engram of normal long-term memory? Can J Neurol Sci 1975;2:385-394.
27. Cutler NR, Post RM. Life course of illness in untreated manic-depressive patients. Compr Psychiatry 1982;23:101-115.
28. Clark M, Post RM, Weiss SRB, et al. Regional expression of c-fos mRNA in rat brain during the evolution of amygdala- kindled seizures. Brain Res Mol Brain Res 1991;11:55-64.
29. Clark M, Weiss SRB, Post RM. Expression of c-fos mRNA in rat brain after intracerebroventricular administration of corticotropin-releasing hormone. Neurosci Lett 1991;132:235-238.
30. Rosen JB, Abramowitz J, Post RM. Co-localization of the TRH mRNA and fos-like immunoreactivity in limbic structures following amygdala kindling. Mol Cell Neurosci 1993;4:335-342.
31. Rosen JB, Cain CJ, Weiss SRB, et al. Alterations in mRNA of enkephalin, dynorphin, and thyrotropin-releasing hormone during amygdala kindling: an in situ hybridization study. Brain Res Mol Brain Res 1992;15:247-255.
32. Smith M, Weiss SRB, Abedin T, et al. Effects of amygdala- kindling and electroconvulsive seizures on the expression of corticotropin-releasing hormone (CRH) mRNA in the rat brain. Mol Cell Neurosci 1991;2:103-116.
33. Sutula TP, Golarai G, Cavazos J. Assessing the functional significance of mossy fiber sprouting. Epilepsy Res Suppl 1992;7:251-259.
34. Smith MA, Makino S, Kvetnansky R, et al. Stress alters brain derived neurotrophic factor and neurotrophin-3 mRNA levels in the hippocampus [abstract]. Society for Neuroscience Abstracts 1993; 19:866.
35. Meakin SO, Shooter EM. The nerve growth factor family of receptors. Trends Neurosci 1992;15:323-330.
36. Ip NY, Stitt TN, Tapley P, et al. Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron 1993;10:137-149.
37. Davies AM. Cell death and the trophic requirements of developing sensory neurons. In: Scott S, ed. Sensory neurons: diversity, development and plasticity. New York: Oxford University Press, 1992:194-214.
38. Pinel JPJ. Effects of diazepam and diphenylhydantoin on elicited and spontaneous seizures in kindled rats: a double dissociation. Pharmacol Biochem Behav 1983;18:61-63.
39. Weiss SRB, Post RM, Marangos PJ, et al. Peripheral-type benzodiazepines: behavioral effects and interactions with the anticonvulsant effects of carbamazepine. In: Wada J, ed. Kindling III. New York: Raven Press, 1986:375-392.
40. Weiss SRB, Post RM, Szele F, et al. Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine. Brain Res 1989;497:72-79.
41. Donnerer J, Schuliogoi R, Stein C. Increased content and transport of substance P and CGRP in sensory nerves innervating inflamed tissue: evidence for a regulatory role of nerve growth factor in vivo. Neuroscience 1992;49:693-698.
42. McMahon SB, Koltzenburg M. Silent afferents and visceral pain. In: Fields HL, Liebeskind JC, eds. Progress in pain research and management. Seattle: IASP Press, 1994;1:11-30.
43. Nakajima T, Post RM, Weiss SRB, et al. Perspectives on the mechanism of action of electroconvulsive therapy: anticonvulsant, dopaminergic, and c-fos oncogene effects. Conv Ther 1989;5:274-295.
44. Nakajima T, Daval JL, Gleiter CH, et al. c-Fos mRNA expression following electrical-induced seizure and acute nociceptive stress in mouse brain. Epilepsy Res 1989;4:156-159.
45. Banki CM, Karmacsi L, Bissette G, et al. CSF corticotropin- releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neu- ropsychopharmacol 1992;2:107-113.
46. Nemeroff CB, Widerlov E, Bissette G. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984;226:1342-1344.
47. Rubinow DR. Cerebrospinal fluid somatostatin and psychiatric illness. Biol Psychiatry 1986;21:341-365.
48. Arana GW, Baldessarini RJ, Ornsteen M. The dexametha- sone suppression test for diagnosis and prognosis in psychiatry: commentary and review. Arch Gen Psychiatry 1985; 42:1193-1204.
49. Ribeiro SCM, Tandon R, Grunhaus L, et al. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993;150:1618-1628.
50. Post RM, Leverich GS, Altshuler L, et al. Lithium discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992;149:1727-1729.
51. Post RM, Leverich GS, Pazzaglia PJ, et al. Lithium tolerance and discontinuation as pathways to refractoriness. In: Birch NJ, Padgham C, Hughes MS, eds. Lithium in medicine and biology. Carnforth, UK: Marius Press, 1993:71-84.
52. Post RM, Kramlinger KG, Altshuler LL, et al. Treatment of rapid cycling bipolar illness. Psychopharmacol Bull 1990;26: 37-47.
53. Wehr TA, Goodwin FK. Rapid cycling in manic depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979;36:555-559.
54. Post RM. Prophylaxis of bipolar affective disorders. Int Rev Psychiatry 1990;2:277-320.
55. Price DD, Mao J, Mayer DJ. Central neural mechanisms of normal and abnormal pain states. In: Fields HL, Liebeskind JC, eds. Progress in pain research and management. Seattle: IASP Press, 1994;1:61-84.
56. Dickenson AH. NMDA receptor antagonists as analgesics. In: Fields HL, Liebeskind JC, eds. Progress in pain research and management. Seattle: IASP Press, 1994;1:173-187.
57. Edelman GM, Gaily JA. Nitric oxide: linking space and time in the brain. Proc Natl Acad Sci USA 1992;89:11651-11652.
58. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993;5:159-177.
59. Moskowitz MA. Neurogenic vs vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-311.
60. Brown EE, Robertson GS, Fibiger HC. Evidence for conditioned neuronal activation following exposure to a cocaine- paired environment: role of forebrain limbic structures. J Neurosci 1992;12:4112-4121.
61. Campeau S, Hayward MD, Hope BT, et al. Induction of the c-fos proto-oncogene in rat amygdala during unconditioned and conditioned fear. Brain Res 1991;565:349-352.
62. Mendell LM. Physiological properties of unmyelinated fibre projection to the spinal cord. Exp Neurol 1966;16:316-332.
63. Silberstein SD. Current opinion in neurology. Curr Sci 1994; 7:258-263.
64. Olesen J, Edvinsson L. Migraine: a research field matured for the basic neurosciences. Trends Neurosci 1991;14:3-5.
65. Weiss SRB, Post RM. Contingent tolerance to carbamaze- pine: a peripheral-type benzodiazepine mechanism. Eur J Pharmacol 1991;193:159-163.
66. Weiss SRB, Haas K, Post RM. Contingent tolerance to car- bamazepine is associated with lowering of amygdala-kindled seizure thresholds. Exp Neurol 1991;114:300-306.
67. Post RM, Weiss SRB. Endogenous biochemical abnormalities in affective illness: therapeutic vs pathogenic. Biol Psychiatry 1992;32:469-484.
68. Marangell L, George M, Callahan A, et al. Intrathecal thyrotropin-releasing hormone in the treatment of affective disorders: preliminary results of a clinical trial [abstract]. Collegium Internationale Neuropsychopharmaeologieum 1994; 10(part 2):S221.
69. Pazzaglia PJ, Post RM. Contingent tolerance and re-response to carbamazepine: a case study in a patient with trigeminal neuralgia and bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:76-81.
70. Raskin NH. Headache. 2nd ed. New York: Churchill Livingstone, 1988:164-171.
71. Roy-Byrne PP, Post RM, Kellner CH, et al. Ventricular- brain ratio and life course of illness in patients with affective disorder. Psychiatry Res 1987;23:277-284.
72. Post RM, Ketter TA, Denicoff K, et al. Assessment of anticonvulsant drugs in patients with bipolar affective illness. In: Hindmarch I, Stonier PD, eds. Human psychopharmacology: methods and measures. Chichester, England: John Wiley & Sons, 1993:211-245.